Mabwell (Shanghai) Bioscience Co. Ltd. A
Mabwell (Shanghai) Bioscience Co., Ltd., a biopharmaceutical company, engages in the research and development, manufacture, and commercialization of biological products for oncology, immunology, bone disorders, ophthalmology, hematology, and infectious diseases in China and internationally. The company offers MAIWEIJIAN for the treatment of giant cell tumor of bone; MALISHU for the treatment of p… Read more
Mabwell (Shanghai) Bioscience Co. Ltd. A (688062) - Net Assets
Latest net assets as of September 2025: CN¥945.58 Million CNY
Based on the latest financial reports, Mabwell (Shanghai) Bioscience Co. Ltd. A (688062) has net assets worth CN¥945.58 Million CNY as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥4.53 Billion) and total liabilities (CN¥3.58 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥945.58 Million |
| % of Total Assets | 20.89% |
| Annual Growth Rate | 51.89% |
| 5-Year Change | 5.8% |
| 10-Year Change | N/A |
| Growth Volatility | 152.82 |
Mabwell (Shanghai) Bioscience Co. Ltd. A - Net Assets Trend (2017–2024)
This chart illustrates how Mabwell (Shanghai) Bioscience Co. Ltd. A's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Mabwell (Shanghai) Bioscience Co. Ltd. A (2017–2024)
The table below shows the annual net assets of Mabwell (Shanghai) Bioscience Co. Ltd. A from 2017 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥1.56 Billion | -39.54% |
| 2023-12-31 | CN¥2.57 Billion | -26.70% |
| 2022-12-31 | CN¥3.51 Billion | +248.06% |
| 2021-12-31 | CN¥1.01 Billion | -31.41% |
| 2020-12-31 | CN¥1.47 Billion | +94.14% |
| 2019-12-31 | CN¥757.44 Million | +675.26% |
| 2018-12-31 | CN¥-131.67 Million | -257.86% |
| 2017-12-31 | CN¥83.41 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Mabwell (Shanghai) Bioscience Co. Ltd. A's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 461984381027.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | CN¥399.60 Million | 25.47% |
| Other Comprehensive Income | CN¥26.49 Million | 1.69% |
| Other Components | CN¥5.94 Billion | 378.49% |
| Total Equity | CN¥1.57 Billion | 100.00% |
Mabwell (Shanghai) Bioscience Co. Ltd. A Competitors by Market Cap
The table below lists competitors of Mabwell (Shanghai) Bioscience Co. Ltd. A ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
0P0O
LSE:0P0O
|
$949.38 Million |
|
Visionox Technology Inc
SHE:002387
|
$949.47 Million |
|
Luster LightTech Co. Ltd. Cl A
SHG:688400
|
$949.63 Million |
|
Tian Jin Motor Dies Co Ltd
SHE:002510
|
$949.65 Million |
|
Hanma Technology Group Co Ltd
SHG:600375
|
$949.19 Million |
|
Enliven Therapeutics Inc.
NASDAQ:ELVN
|
$948.49 Million |
|
Upbound Group Inc.
NASDAQ:UPBD
|
$948.14 Million |
|
CVS Group plc
PINK:CVSGF
|
$947.94 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Mabwell (Shanghai) Bioscience Co. Ltd. A's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 2,583,701,890 to 1,568,877,364, a change of -1,014,824,526 (-39.3%).
- Net loss of 1,043,919,214 reduced equity.
- Dividend payments of 66,111,902 reduced retained earnings.
- Other comprehensive income decreased equity by 510,639,835.
- Other factors increased equity by 605,846,425.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥-1.04 Billion | -66.54% |
| Dividends Paid | CN¥66.11 Million | -4.21% |
| Other Comprehensive Income | CN¥-510.64 Million | -32.55% |
| Other Changes | CN¥605.85 Million | +38.62% |
| Total Change | CN¥- | -39.28% |
Book Value vs Market Value Analysis
This analysis compares Mabwell (Shanghai) Bioscience Co. Ltd. A's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 8.44x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 112.86x to 8.44x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | CN¥0.29 | CN¥33.11 | x |
| 2018-12-31 | CN¥-0.50 | CN¥33.11 | x |
| 2019-12-31 | CN¥2.59 | CN¥33.11 | x |
| 2020-12-31 | CN¥3.68 | CN¥33.11 | x |
| 2021-12-31 | CN¥2.53 | CN¥33.11 | x |
| 2022-12-31 | CN¥8.80 | CN¥33.11 | x |
| 2023-12-31 | CN¥6.47 | CN¥33.11 | x |
| 2024-12-31 | CN¥3.92 | CN¥33.11 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Mabwell (Shanghai) Bioscience Co. Ltd. A utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -66.54%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -522.53%
- • Asset Turnover: 0.05x
- • Equity Multiplier: 2.73x
- Recent ROE (-66.54%) is below the historical average (-62.51%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2017 | -123.16% | -2231.90% | 0.01x | 7.63x | CN¥-111.06 Million |
| 2018 | 0.00% | -602.59% | 0.04x | 0.00x | CN¥-211.12 Million |
| 2019 | -122.63% | -3153.34% | 0.03x | 1.42x | CN¥-1.00 Billion |
| 2020 | -43.69% | -12118.54% | 0.00x | 1.11x | CN¥-789.61 Million |
| 2021 | -76.14% | -4742.85% | 0.01x | 1.58x | CN¥-870.67 Million |
| 2022 | -27.17% | -3445.00% | 0.01x | 1.31x | CN¥-1.31 Billion |
| 2023 | -40.77% | -824.05% | 0.03x | 1.72x | CN¥-1.31 Billion |
| 2024 | -66.54% | -522.53% | 0.05x | 2.73x | CN¥-1.20 Billion |
Industry Comparison
This section compares Mabwell (Shanghai) Bioscience Co. Ltd. A's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,043,310,248
- Average return on equity (ROE) among peers: 14.20%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Mabwell (Shanghai) Bioscience Co. Ltd. A (688062) | CN¥945.58 Million | -123.16% | 3.79x | $949.30 Million |
| Shenzhen CAU Technology Co Ltd (000004) | $124.02 Million | 4.50% | 1.13x | $80.66 Million |
| Pacific Shuanglin Bio pharmacy Co Ltd (000403) | $525.49 Million | 14.76% | 1.41x | $1.02 Billion |
| Nanhua Bio Medicine Co Ltd (000504) | $174.34 Million | 36.11% | 1.61x | $288.51 Million |
| Jiangsu Sihuan Bioengineering Co Ltd (000518) | $642.80 Million | -4.58% | 0.44x | $244.62 Million |
| Chengzhi Shareholding Co Ltd (000990) | $1.69 Billion | 3.06% | 0.97x | $850.04 Million |
| Hualan Biological EngineeringInc (002007) | $1.86 Billion | 32.78% | 0.08x | $2.00 Billion |
| Da An Gene Co Ltd of Sun Yat-Sen University (002030) | $2.09 Billion | 4.42% | 0.71x | $784.18 Million |
| Shanghai RAAS Blood Products Co Ltd Class A (002252) | $831.21 Million | 22.32% | 0.12x | $3.76 Billion |
| Baolingbao Biology Co Ltd (002286) | $2.04 Billion | 5.44% | 0.31x | $398.99 Million |
| Tibet Cheezheng Tibetan Medicine Co Ltd (002287) | $456.61 Million | 23.20% | 0.29x | $347.95 Million |